logo
Ships carrying enslaved people wrecked amid revolts in 1700s. Now they're found

Ships carrying enslaved people wrecked amid revolts in 1700s. Now they're found

Miami Herald29-04-2025

Centuries after Danish ships carrying enslaved people from West Africa disappeared in the Caribbean, the charred and destroyed remains have been identified for the first time.
In 2023, researchers and archaeologists from the National Museum of Denmark and the Viking Ship Museum put on their dive gear and visited two known shipwreck sites off Cahuita National Park in Costa Rica, according to an April 27 news release from the National Museum published in Ritzaus Bureau.
'For many years, however, they were thought to be pirate ships,' researchers said. 'But when American marine archaeologists in 2015 found yellow bricks in one of the wrecks, new questions emerged about the history of the ships.'
Hoping to find answers, the archaeologists brought samples of the bricks and wood to the surface to determine where it originated, according to the release.
The researchers used dendrochronology, or the study of tree rings, to determine the wood for one wreck came from the western region of the Baltic Sea, which included a region of Germany and Denmark, according to the release.
Dating of the wood showed it was cut down between 1690 and 1695, researchers said, and it was 'charred and sooty.'
When they analyzed the bricks, they found the brick matched Flensburg bricks produced in Denmark and the Danish colonies, and the clay used to make them was collected in Denmark, researchers said. The bricks were dated to the 18th century.
Among the wreckage, the divers also found Dutch-produced pipes with sizes and patterns suggesting they were made at the beginning of the 18th century, according to the release.
At this point, there was no doubt where the ships originated: Denmark.
But, how did they make their way to the Costa Rican coast? And how had their journeys come to such violent ends?
'According to historical sources, the two Danish slave ships Fridericus Quartus and Christianus Quintus were shipwrecked off the coast of Central America in 1710,' researchers said. 'Fridericus Quartus was set ablaze, while Christianus Quintus had its anchor rope cut, following which the ship was wrecked in the surf. Until now, it has not been clear exactly where the ships were lost.'
The ships are considered part of darkest chapters of Danish history, according to an April 28 Facebook post from the Viking Ship Museum.
The two ships were blown hundreds of miles off course as they traveled across the Atlantic from West Africa as part of the trade of enslaved people, according to the museum.
In the spring of 1710, the ships finally saw land, but the environment on board was dangerously tense, the museum said.
The crew and 600-700 enslaved people had resorted to eating only turtles caught off the ship by the end of the journey, and after the surviving West Africans were dropped on shore, there was a mutiny, according to the museum.
The anchors of one ship were cut, allowing it to crash into the coral reef and sink, and the second ship was set ablaze, eventually also reaching the seafloor.
Some members of the crew had boarded English vessels, eventually making their way back to Denmark and writing about their previous voyage, but none of the sailors wrote where the ships met their end, the museum said.
A video about the expedition was shared by the National Museum of Denmark on April 28.
Cahuita National Park is on the southeastern coast of Costa Rica along the Caribbean Sea.
Facebook Translate was used to translate the post from the Viking Ship Museum.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Is it true that … cold water plunges boost immunity?
Is it true that … cold water plunges boost immunity?

Yahoo

time3 hours ago

  • Yahoo

Is it true that … cold water plunges boost immunity?

'It's a long-held belief that taking to the waters is good for your health,' says Mike Tipton, a professor of human and applied physiology at the University of Portsmouth. From Roman frigidariums to Thomas Jefferson's foot baths, cold immersion has long been seen as curative. But does modern science support the idea that it boosts immunity? The answer: it's complicated. While cold water immersion does activate the body, that's not the same as strengthening the immune system. 'When you immerse yourself in cold water, your body undergoes the cold shock response,' says Tipton. 'You get rapid breathing, a spike in heart rate and a surge of stress hormones such as adrenaline and cortisol.' This may explain why people feel more alert or energised after a cold dip. But does it mean you're less likely to get sick? Many studies into the effects focus on immune cell activity in the blood – which can increase after cold exposure – but that doesn't always translate into fewer infections. 'It's easy to cherry-pick results,' says Tipton. He points to a frequently quoted Dutch study in which people who ended their daily hot showers with at least 30 seconds under cold water took 29% fewer sick days. While it's often used as an example of the powers of cold plunges, those participants actually reported the same number of infections as those who didn't have a cold shower. 'That might reflect increased resilience or just a willingness to push through because of being part of a study,' says Tipton, rather than better immunity. It may also be that regular cold plungers simply have a healthier lifestyle overall. A recent study by Tipton's team found that indoor and outdoor swimmers had fewer respiratory infections than non-swimmers, suggesting it may be the exercise, not the cold, doing the work. One thing is clear: too much cold is harmful. 'If your core temperature drops too far, it can suppress the immune system,' he says. His advice? Keep it short – no more than 90 seconds.

Newsflash: Rocket Lab Makes Spy Satellites Now
Newsflash: Rocket Lab Makes Spy Satellites Now

Yahoo

time4 hours ago

  • Yahoo

Newsflash: Rocket Lab Makes Spy Satellites Now

Rocket Lab will buy spy satellite payload manufacturer Geost for up to $325 million in cash and stock. Rocket Lab already makes satellite buses for spy agencies and the military. Geost will allow it to make complete spy satellites. The purchase could help Rocket Lab bid for contracts under President Trump's Golden Dome plan. 10 stocks we like better than Rocket Lab › Rocket Lab (NASDAQ: RKLB) stock has taken off like -- what else? -- a rocket. Over the past 52 weeks, shares of the maker of tiny satellites and the only slightly bigger rockets that launch them has soared 521%, gaining about 10% per week. At nearly $27 per share currently, Rocket Lab carries a market capitalization of more than $13.3 billion, and is valued at 31 times its annual sales. Whatever might Rocket Lab be able to do to justify such an optimistic valuation? That's the question I asked myself (and CEO Peter Beck) when I interviewed him about the company's plans to build a new Neutron rocket -- and about the company's plans beyond Neutron -- a couple years back. And I came away with the firm opinion that Rocket Lab's most likely course, to expand its revenue streams and help justify its steadily increasing market capitalization, would be to build (or buy) its own satellite constellation. Turns out, though, Rocket Lab has decided to take neither of these routes, or at least not for now. Instead, Rocket Lab's next act will be to begin making spy satellites, and become a prime contractor selling such satellites directly to American spy agencies and the military. Rocket Lab's path to this new business goes by way of Geost, LLC, a tiny privately owned manufacturer of electro-optical payloads for the spy satellite market. Last week, Rocket Lab announced it will pay $125 million cash, plus $150 million in Rocket lab stock, plus another $50 million cash "in potential additional cash earnout payments tied to revenue targets" to buy Geost from the private equity firm that currently owns it. The purchase is slated to take place sometime in the second half of 2025. Once it happens, Rocket Lab will be able to build its own spy satellite "payloads," to couple with the satellite "buses" that it already builds to carry other companies' payloads. "Geost delivers advanced EO/IR sensor systems for missile warning and tracking, tactical intelligence, surveillance, and reconnaissance, Earth observation, and space domain awareness," explains Rocket Lab, referring to electro-optical and infrared sensors (or in more common parlance, "cameras"). Rocket Lab notes that these are precisely the kinds of cameras that the U.S. Pentagon is currently deploying en masse as part of the Space Force's Proliferated Warfighter Space Architecture (PWSA) program, for which Rocket Lab won a $515 million contract in 2023. These same kinds of cameras would be needed in even greater numbers to construct President Donald Trump's Golden Dome. Geost has until now been building these sensor suites for sale to major defense contractors such as Northrop Grumman and L3Harris, both of which are also major players in PWSA, and both of which are hopefuls for the Golden Dome project. Now, Geost will bring these capabilities in-house and help Rocket Lab to build entire spy satellites directly, "cementing the Company's role as a disruptor in national security space," and allowing the company to provide even more "end-to-end space capabilities for the United States and its allies." Simply put, it gives Rocket Lab a huge leg up in competing for future awards under PWSA, under Golden Dome, and for other spy satellite work -- not just for the U.S., but internationally as well. And let's be honest here: Rocket Lab really needs a boost like this, if its enormous valuation is to be justified. Priced in excess of $12.3 billion, but with less than $500 million in annual revenue and no profit or free cash flow, and not expected to turn profitable for another couple of years at least, Rocket Lab stock sells for a sky-high valuation of 26 times sales. Even assuming analyst forecasts are correct, it will be 2030 before Rocket Lab's sales (projected to be $3.5 billion that year) reach a level that brings the stock down to an ordinary valuation for a space stock -- somewhere between 2 and 4 times sales. Granted, growth stocks like Rocket Lab often sport excessive valuations to present-day sales. But to justify its valuation, Rocket Lab needs a really big growth driver, capable of rapidly expanding its annual sales. Buying Geost, and putting itself in contention to win prime contracts under the $175 billion Golden Dome project, just might be a catalyst big enough to make that happen. Before you buy stock in Rocket Lab, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Rocket Lab wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $674,395!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $858,011!* Now, it's worth noting Stock Advisor's total average return is 997% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Rich Smith has positions in Rocket Lab USA. The Motley Fool has positions in and recommends L3Harris Technologies and Rocket Lab USA. The Motley Fool has a disclosure policy. Newsflash: Rocket Lab Makes Spy Satellites Now was originally published by The Motley Fool Sign in to access your portfolio

Menopause drug might prevent breast cancer and treat hot flashes, research finds
Menopause drug might prevent breast cancer and treat hot flashes, research finds

New York Post

time2 days ago

  • New York Post

Menopause drug might prevent breast cancer and treat hot flashes, research finds

A drug intended to treat menopause symptoms could double as breast cancer prevention. New research from Northwestern University in Illinois found that Duavee, a Pfizer-made drug, 'significantly reduced' breast tissue cell growth, which is a major indicator of cancer progression. Advertisement A phase 2 clinical trial included 141 post-menopausal women who had been diagnosed with ductal carcinoma in situ (DCIS), also known as stage 0 breast cancer, according to a press release from Northwestern. This non-invasive breast cancer affects more than 60,000 American women each year, often leading to an outcome of invasive breast cancer. The women were separated into two groups — one received Duavee and the other took a placebo for a month before undergoing breast surgery. Duavee is a conjugated estrogen/bazedoxifene (CE/BZA) drug, which combines estrogen with another medication that minimizes the potential harmful side effects of the hormone. Advertisement 'The key takeaway from the study is that CE/BZA slows the growth (proliferation) of cells in milk ducts of DCIS that expressed the estrogen receptor significantly more than placebo,' Dr. Swati Kulkarni, lead investigator and professor of breast surgery at Northwestern University Feinberg School of Medicine, told Fox News Digital. 5 New research from Northwestern University found that the drug Duavee 'significantly reduced' breast tissue cell growth, a major indicator of cancer progression. Marko Geber – Another major finding is that the quality of life did not differ significantly between the two groups, but patients who took the CE/BZA reported fewer hot flashes during the study, she noted. 'This would be expected, as the drug is FDA-approved to treat hot flashes.' Advertisement Kulkarni presented the study last week at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. 5 The women in the study were separated into two groups — one received Duavee and the other took a placebo for a month before undergoing breast surgery. Gorodenkoff – 5 Those who took the drug reported fewer hot flashes during the study. fizkes – The findings are preliminary and have not yet been published in a medical journal. Advertisement 'What excites me most is that a medication designed to help women feel better during menopause may also reduce their risk of invasive breast cancer,' said the doctor, who is also a Northwestern Medicine breast surgeon. Women who face a higher risk of breast cancer — including those who have experienced 'high-risk lesions' — and who also have menopausal symptoms are most likely to benefit from the drug, according to Kulkarni. 'These women are typically advised against standard hormone therapies, leaving them with few menopausal treatment options,' the release stated. Study limitations The researchers said they are 'encouraged' by these early results, but more research is required before the medication can be considered for approval as a breast cancer prevention mechanism. 'Our findings suggest that CE/BZA may prevent breast cancer, but larger studies with several years of follow-up are needed before we would know this for sure,' Kulkarni told Fox News Digital. Dr. Sheheryar Kabraji, chief of breast medicine at the Roswell Park Comprehensive Cancer Center in Buffalo, New York, was not involved in the study but commented on the findings. 5 'What excites me most is that a medication designed to help women feel better during menopause may also reduce their risk of invasive breast cancer,' Dr. Swati Kulkarni said. sarayutsridee – Advertisement 'While intriguing, this study is highly preliminary, and more research will be needed before we can conclude that conjugated estrogen/bazedoxifene (CD/BZA), a form of the hormone estrogen commonly prescribed to address symptoms of menopause, prevents invasive breast cancer or is effective at reducing cancer risk,' he told Fox News Digital. Kabraji also noted that the study focused on reducing levels of one specific protein, 'which does not always predict reduced recurrence of breast cancer.' 'This study did not directly show that CE/BZA treatment reduces the risk of DCIS recurrence or development of invasive cancer,' he noted. 5 According to Kulkarni,'larger studies with several years of follow-up are needed' to confirm that the drug prevents breast cancer. Science RF – Advertisement 'Importantly, however, patients who received this therapy experienced no worsening of quality of life, and saw improvement in vasomotor symptoms, such as hot flashes. If found to be effective in preventing breast cancer, CE/BZA is likely to have fewer side effects than current medications used for breast cancer prevention.' Lead researcher Kulkarni emphasized that this medication is not for the treatment of invasive breast cancer or DCIS. 'Right now, we can say that women who are concerned about their risk of developing breast cancer can consider this medication to treat their menopausal symptoms,' she added.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store